Selank Research Guide: Anxiolytic Peptide Mechanisms, Cognitive Enhancement, and Immune Modulation
Shop Our Top Compounds
All information presented in this article is for research purposes only. Selank is not FDA-approved and is not intended for human consumption. The following content summarizes published scientific literature and does not constitute medical advice, treatment recommendations, or dosage guidance. Selank is classified among certain bulk drug substances under investigation and is sold exclusively for laboratory research.
Introduction: What Is Selank Peptide?
Among the emerging class of regulatory peptides being investigated for neuropsychiatric and immunological applications, the peptide selank (also designated TP-7) has attracted significant scientific attention. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences under the leadership of Nikolai Myasoedov, Selank is a synthetic peptide developed as a heptapeptide analog of the naturally occurring immune peptide tuftsin, also known as the endogenous peptide tuftsin (Thr Lys Pro Arg). The molecule was engineered by appending a stabilizing Pro-Gly-Pro glyproline sequence to the C-terminus of tuftsin, yielding the full sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. This structural modification creates one of the stable regulatory glyproline peptides that dramatically improves metabolic stability and extends the duration of biological activity compared to native tuftsin, which is rapidly degraded by endogenous peptidases (Ashmarin et al., 2005).
Selank peptide research has expanded considerably since its initial characterization in the 1990s. Published studies have documented anxiolytic, nootropic, neuroprotective, and immunomodulatory properties—spanning GABAergic modulation, serotonin metabolism, brain derived neurotrophic factor (BDNF) upregulation, enkephalin stabilization, and cytokine regulation. Approved in Russia as an anxiolytic medication for generalized anxiety disorder (GAD) and neurasthenia, Selank remains unapproved by the FDA and is classified as a research compound in most Western jurisdictions. Unlike benzodiazepine tranquilizers and traditional medications used for anxiety disorders, research suggests that Selank does not present significant safety risks such as sedation, cognitive dulling, or dependency risks.
Composed entirely of natural L amino acids, this synthetic peptide belongs to the broader class of physiologically active compounds that modulate the central nervous system through multiple convergent pathways. This comprehensive guide examines the peer-reviewed literature on Selank’s multifaceted molecular mechanisms of action, its comparison with related neuropeptides and classical anxiolytics, and the implications of current findings for ongoing peptide research. For foundational peptide terminology, consult our Peptide Reconstitution Guide.
Selank Mechanism of Action in the Central Nervous System
Understanding the Selank mechanism of action requires appreciating that this peptide does not operate through a single receptor pathway. Instead, research has revealed a convergent, multi-system mechanism involving allosteric modulation of GABA receptors, serotonergic system influence, and downstream gene expression changes affecting dozens of neurotransmission-related targets in the central nervous system. Selank’s actions do not rely on specific ligand receptor interactions at a single site but rather engage a network of interconnected signaling pathways.
Allosteric Modulation of GABA Receptors
The most thoroughly investigated molecular mechanism underlying Selank’s anxiolytic effects involves allosteric modulation of the type-A gamma-aminobutyric acid receptor (GABA-A). Clinical studies first prompted this hypothesis: researchers noted that the anxiolytic profile of Selank closely mirrors that of classical benzodiazepine tranquilizers—drugs known to act as positive allosteric modulators of GABA receptors—yet without the characteristic side effects of sedation, amnesia, withdrawal syndrome, or dependence (Seredenin et al., 1998).
Radioligand binding studies by Vyunova et al. (2018), published in a landmark paper on the molecular aspects of heptapeptide Selank biological activity, provided direct molecular evidence. Using [³H]GABA binding assays on rat brain plasma membranes, the researchers demonstrated that Selank functions as a positive allosteric modulator of GABA-A receptors in a subtype-selective, concentration-dependent manner. Critically, Selank’s modulation was distinct from that of benzodiazepines: it was shown to block the modulatory activity of diazepam and olanzapine, suggesting that the peptide and benzodiazepine binding sites are not identical but may partially overlap. This allosteric rather than orthosteric mechanism likely explains why Selank produces anxiolysis without the sedation, cognitive impairment, and addiction potential that limit classical benzodiazepine utility.
How Selank Administration Affects GABAergic Gene Expression
The landmark gene expression study by Volkova et al. (2016), published in Frontiers in Pharmacology, dramatically expanded the picture of how Selank administration affects the gabaergic system. Using RT-qPCR arrays, the researchers analyzed expression of 84 genes involved in gabaergic neurotransmission in the rat frontal cortex at 1 and 3 hours following intranasal administration of Selank (300 μg/kg). The results were striking:
- 45 genes showed statistically significant expression changes within 1 hour of Selank or GABA administration
- A strong positive correlation (r = 0.86, p ≤ 0.05) was observed between Selank- and GABA-induced gene expression changes at 1 hour
- Selank modulated expression of GABA receptor subunit genes (Gabrb3, Gabre, Gabrq), GABA transporters (Slc6a1, Slc6a11, Slc32a1), dopamine receptors (Drd1a, Drd2, Drd3, Drd5), serotonin receptors (Htr3a, Htr1b), and ion channels (Cacna1a, Cacna1b)
- At 3 hours, Selank maintained expression changes in 17 genes (22%), while GABA effects had largely subsided to only 9 genes (12%), indicating a more sustained pharmacological action for the peptide
This temporal divergence is significant for selank peptide research: it suggests that Selank administration activates secondary signaling cascades beyond direct GABA-A modulation, consistent with additional mechanisms through dopaminergic and serotonergic systems.
Serotonin Metabolism, Monoamine Modulation, and Mood Regulation
Research by Narkevich et al. (2008) documented Selank’s effects on monoamine neurotransmitter levels in BALB/c and C57Bl/6 mouse brains. Administration of the tuftsin analog peptide influenced both serotonin (5-HT) and its metabolite concentrations in hypothalamic and cortical regions. Semenova et al. (2009) further demonstrated that Selank affects behavioral outcomes through serotonergic pathways, as effects were partially attenuated by pretreatment with para-chlorophenylalanine (PCPA), a serotonin synthesis inhibitor, confirming a functional serotonergic component to its mechanism. The peptide Selank appears to optimize serotonin metabolism rather than simply increasing or decreasing 5-HT levels—a “normalizing” or adaptogenic-type action consistent with its favorable side-effect profile and role in mood regulation.
Selank Anxiolytic Properties: Reducing Anxiety Without Sedation
The peptide anxiolytic Selank profile represents one of the most compelling aspects of this peptide. Unlike benzodiazepines, barbiturates, and other conventional anxiolytics that achieve anxiolysis at the cost of sedation, psychomotor impairment, and dependence risk, Selank has consistently demonstrated anxiolytic-equivalent efficacy with a notably clean side-effect profile across both preclinical and clinical studies. Research suggests that the mechanism of reducing anxiety through Selank involves modulating multiple neurotransmitter systems simultaneously rather than blunting neural activity globally.
Preclinical Evidence: Reducing Anxiety Levels in Animal Models
The foundational anxiolytic characterization was reported by Seredenin et al. (1998), who studied the TP-7 peptide in inbred mouse strains (BALB/c and C57Bl/6) selected for divergent emotional stress phenotypes and stress response patterns. When Selank administered to these animals, the peptide reduced anxiety levels in elevated plus maze and open field paradigms across both mouse strains, demonstrating strain-independent anxiolytic efficacy. Notably, the peptide also exhibited antistress and positive emotional effects without sedation or motor impairment.
Kozlovskaya et al. (2003), publishing in the journal Neuroscience and Behavioral Physiology, extended these findings to outbred rats under acute stress conditions, confirming that Selank and related tuftsin-family peptides exerted positive emotional effects and antistress actions. Individual behavioral responses varied with molecular structure, establishing structure-activity relationships within the tuftsin family.
Kasian et al. (2017) compared Selank’s anxiolytic effects directly against diazepam using the unpredictable chronic mild stress (UCMS) model in rats—a paradigm with high translational relevance for generalized anxiety disorders. The study, published in Disease Markers, demonstrated that the peptide Selank enhances the anxiolytic effect of diazepam and produced comparable anxiety reduction as monotherapy, while additionally upregulating orexin-related gene expression (potentially explaining the absence of sedation).
Clinical Trial Evidence for Generalized Anxiety Disorder
In a clinical study of 62 participants with generalized anxiety disorder and neurasthenia, Zozulia et al. (2008) investigated the therapeutic effects of the new peptide anxiolytic Selank against medazepam (a benzodiazepine). The anxiolytic effects of both agents were reported as similar in magnitude, but Selank additionally demonstrated antiasthenic and psychostimulant effects absent from the benzodiazepine group. The clinical-biological analysis revealed that Selank’s mechanism involved modulation of serotonin metabolism and enkephalin system activity—effects not shared with traditional anxiolytics.
A separate clinical comparison with phenazepam in subjects with phobic-anxiety and somatoform disorders further confirmed Selank’s comparable anxiolytic potency with superior tolerability (Medvedev et al., 2014). These clinical studies underscore the potential of Selank peptide as a research tool for investigating novel anxiolytic mechanisms without the dependency risks and cognitive dulling associated with conventional GABAergic drugs.
For researchers interested in how Selank compares with other neuropeptides under investigation, see our Semax research overview and Research Articles hub.
Enkephalin Stabilization: The Endogenous Opioid Connection
One of the most distinctive aspects of Selank mechanism of action involves its potent inhibition of enkephalin-degrading enzymes (enkephalinases), which effectively prolongs the activity of endogenous opioid peptides—the body’s own natural anxiolytics and analgesics. This mechanism operates within the central nervous system to amplify existing regulatory signals.
Enkephalinase Inhibition and Functional Significance
Zozulya et al. (2001) published a pivotal study demonstrating that individuals with generalized anxiety disorders exhibited significantly shortened enkephalin half-life and reduced total enkephalinase activity in blood compared to healthy controls. This finding implicated dysregulated endogenous opioid metabolism in the pathophysiology of anxiety disorders. The researchers then tested Selank’s effect on enkephalin degradation and found that the peptide dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin with an IC₅₀ of 15 μM. Remarkably, Selank proved more potent than established peptidase inhibitors bacitracin and puromycin in suppressing enkephalinase activity.
Kost et al. (2001) confirmed these findings and extended them to include Semax (Met-Glu-His-Phe-Pro-Gly-Pro), another Russian-developed heptapeptide. Both synthetic peptide compounds inhibited enkephalin-degrading enzymes from human serum in a dose-dependent manner, though through potentially distinct mechanisms reflective of their differing parent peptide origins (tuftsin versus ACTH₄₋₁₀).
By stabilizing endogenous enkephalins rather than directly activating opioid receptors, Selank amplifies the body’s own regulatory opioid signaling in nerve cells without the tolerance, dependence, and reward circuit activation associated with exogenous opioid agonists. Meshavkin et al. (2006) demonstrated that Selank’s modulatory effect on dopamine system hyperfunction was blocked by naloxone (an opioid receptor antagonist), confirming that opioid pathway involvement is integral to the peptide’s neuropsychotropic activity.
Brain Derived Neurotrophic Factor Upregulation and Neuroprotective Effects
Research has demonstrated that Selank administration influences the expression of brain derived neurotrophic factor (BDNF), a critical neurotrophin involved in synaptic plasticity, neuronal survival, and memory consolidation. BDNF dysregulation has been implicated in anxiety disorders, depression, and neurodegenerative conditions, making it a high-value research target. Research suggests that Selank’s BDNF-enhancing properties may contribute to both its anxiolytic and cognitive-enhancing effects.
Hippocampal BDNF Expression and Cognitive Support
Studies have shown that Selank administration upregulates BDNF mRNA expression in the hippocampus, a brain region central to memory formation and emotional regulation. This BDNF-enhancing effect provides notable cognitive support and is particularly relevant because reduced hippocampal BDNF levels are consistently observed in animal models of chronic stress and depression.
The neuroprotective dimension of Selank biological activity was further demonstrated by Kolik et al. (2019), who investigated the peptide’s capacity to protect against ethanol-induced cognitive impairment in aged rats—a model relevant to chronic alcohol use and chronic alcohol-related neurodegeneration. In published studies, researchers administered Selank at 0.3 mg/kg/day intraperitoneally for 7 days and observed significant cognitive-stimulating effects and protection of memory function, supporting a neuroprotective mechanism consistent with BDNF pathway activation. These findings are relevant to research on age related memory disturbances and cognitive disorders.
Orexin System Activation
The Volkova et al. (2016) gene expression study revealed another intriguing neuroprotective finding: Selank produced a massive 128-fold upregulation of hypocretin (orexin) gene expression at the 3-hour time point. Orexins regulate the balance between sleep and wakefulness, and this activation may explain Selank’s documented absence of hypnosedative effects (which are common with benzodiazepines) while simultaneously contributing to its antiasthenic and psychostimulant properties observed in clinical studies.
Selank Cognitive Enhancement: Learning, Memory, and Cognitive Function
The Selank cognitive enhancement properties documented in published research extend beyond general neuroprotection to specific improvements in learning acquisition, memory consolidation, cognitive function, and memory trace stability. These nootropic effects position Selank as a unique compound that bridges anxiolytic and cognitive research domains.
Learning Acceleration and Memory Processes in Animal Models
Kozlovskii and Danchev (2002) investigated Selank’s effects on active avoidance conditioning in rats. In published studies, the researchers found that even a single administration of Selank significantly improved learning and memory processes in rats with initially low learning ability, with effects apparent from the first Selank dose on training day 1. This rapid onset of cognitive facilitation distinguishes Selank from many nootropic agents that require extended administration periods.
Semenova et al. (2010) conducted a detailed investigation of Selank’s optimization of learning and memory processes. Key findings included:
- A single injection of Selank activated serotonin (5-HT) metabolism in the hypothalamus and caudal brain stem for 30 minutes to 2 hours
- Selank induced increases in memory trace stability lasting up to 30 days following administration
- The peptide’s cognitive effects were mediated in part through serotonergic and catecholaminergic pathways
Cognitive Restoration After Neurochemical Damage
Semenova et al. (2007) demonstrated that Selank (administered at 300 μg/kg in published research protocols) restored cognitive processes and cognitive function that had been disrupted by chronic artificial inhibition of the cerebral catecholaminergic system during early ontogeny. This finding is significant because it suggests that Selank may possess restorative rather than merely enhancing cognitive properties—a characteristic with implications for research into neurodevelopmental conditions and cognitive disorders.
For a broader overview of peptides investigated for cognitive effects, see our Research Articles section and explore related peptides such as Pinealon and Semax.
Immune Modulation: Cytokine Regulation and Antiviral Properties
As a derivative of tuftsin—itself a fragment of immunoglobulin G and a naturally occurring immune peptide with established immunomodulatory properties—Selank retains and extends the immune-regulatory functions of its parent molecule. The immune modulation effects documented in Selank research span cytokine balance, monocyte activation, and antiviral defense, reflecting its origins as a tuftsin-derived synthetic peptide.
Cytokine Regulation, IL-6 Modulation, and Immune System Effects
Uchakina et al. (2008) investigated the immunomodulatory effects of Selank in subjects with anxiety-asthenic disorders. The study revealed significant cytokine-regulating effects on the immune system, with Selank affects on IL-6 and other inflammatory mediator levels. The authors concluded that Selank functions as a novel immunomodulator with dual neuropsychiatric and immune-regulatory activity—a combination consistent with the growing understanding that anxiety disorders involve neuroinflammatory components.
Additional preclinical research from the department of human genetics and molecular genetics has examined Selank’s effects on cytokine profiles under conditions of social stress, demonstrating modulation of pro-inflammatory and anti-inflammatory cytokine balance (Vyunova et al., 2020). This immune modulation profile shares functional similarities with other peptides investigated for dual neural-immune activity. For comparison, explore research peptides like Thymosin Alpha-1 and KPV.
Antiviral Activity and Immune Defense
Ershov et al. (2009) evaluated Selank’s antiviral properties against influenza virus in both in vitro and in vivo experimental biology models. The findings from the department of experimental pharmacology suggested that the mechanism of Selank’s antiviral action was related to its ability to modulate the Th1/Th2/Treg cytokine equilibrium, both directly and through effects on monocyte and macrophage activation. This positions the synthetic peptide Selank within the broader category of immunomodulatory peptides that enhance antiviral defense through immune system optimization rather than direct viricidal activity.
Gene Expression: Broad-Spectrum Transcriptomic Effects
The scope of Selank’s influence on gene expression extends well beyond the gabaergic system. Kolomin et al. (2013) analyzed transcriptome alterations in the rat hippocampus following Selank treatment and identified changes in genes involved in neurotransmission, signal transduction, and neuronal plasticity. Combined with the Volkova et al. (2016) frontal cortex data showing statistically significant changes in 45+ genes across GABA receptor subunits, dopamine receptors, serotonin receptors, ion channels, transporters, and transcription factors, the emerging picture is of a peptide with remarkably broad transcriptomic influence.
This multi-target gene expression profile is consistent with the concept of Selank as a “regulatory” rather than “pharmacological” agent—modulating complex neurobiological networks in nerve cells rather than engaging a single molecular target. Research from the Institute of Molecular Genetics continues to explore how these transcriptomic changes translate to the observed behavioral and immunological effects of Selank peptide.
Safety Profile: Research Suggests Selank Does Not Present Significant Safety Risks
One of the most notable features distinguishing Selank from conventional anxiolytic compounds is its favorable safety profile documented across published research. Unlike benzodiazepine tranquilizers and related drugs that present significant safety risks including sedation, tolerance, dependence, and withdrawal syndrome, research suggests that Selank safety data from available studies shows a markedly different profile. Published clinical studies have not reported significant safety risks such as cognitive impairment, motor dysfunction, dependency risks, or withdrawal effects.
The absence of side effects common to GABAergic drugs is likely attributable to Selank’s distinct mechanism: allosteric modulation through a non-benzodiazepine site on GABA receptors, combined with concurrent orexin system activation that counteracts sedation. This stands in marked contrast to traditional medications for anxiety disorders that frequently cause cognitive dulling and carry dependency risks.
Intranasal Selank has been the primary formulation studied in clinical settings, and published research on this route of administration has consistently noted favorable tolerability. Injectable Selank has been used in preclinical research protocols with similarly favorable safety observations. It is important to note that while safety data is encouraging, Selank remains classified among certain bulk drug substances requiring further investigation, and all safety assessments should be interpreted within the context of controlled research settings.
For proper handling of research peptides, consult our Peptide Storage Guide and Peptide Reconstitution Guide.
Selank vs. Semax, Diazepam, and Phenibut: Comparative Analysis
Understanding the peptide selank requires contextualizing it against related compounds used in anxiety and cognitive research.
Selank vs. Semax: Both Selank and Semax were developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and share the C-terminal Pro-Gly-Pro glyproline stabilizing sequence as stable regulatory glyproline peptides. However, their parent peptides and primary mechanisms differ substantially:
| Feature | Selank | Semax |
|---|---|---|
| Parent Peptide | Tuftsin (IgG fragment, naturally occurring immune peptide) | ACTH₄₋₁₀ (melanocortin fragment) |
| Primary Mechanism | GABA-A allosteric modulation | BDNF/NGF upregulation, melanocortin pathways |
| Primary Profile | Anxiolytic > Nootropic | Nootropic > Anxiolytic |
| Immune Effects | Immunomodulatory (tuftsin-derived) | Neuroprotective, anti-inflammatory |
| Enkephalinase Inhibition | Potent (IC₅₀ 15 μM) | Present but less characterized |
| Serotonin Effects | Metabolism optimization, mood regulation | Modulation via BDNF pathways |
Panikratova et al. (2020) directly compared the two peptides using resting-state fMRI in human subjects, demonstrating distinct whole-brain functional connectivity patterns: Selank primarily influenced limbic-cortical connectivity (consistent with anxiolytic action), while Semax showed greater effects on prefrontal and attention-related networks (consistent with nootropic emphasis). Both peptides demonstrated activity patterns consistent with their influence on cognitive function and mood regulation.
Selank vs. Diazepam: While both agents target the gabaergic system, their mechanisms fundamentally differ. Diazepam acts as a direct positive allosteric modulator at the benzodiazepine binding site of GABA-A receptors, producing potent anxiolysis accompanied by sedation, cognitive impairment, muscle relaxation, and dependence liability. The Selank dose used in research modulates GABA-A receptors through a distinct allosteric site and additionally engages enkephalin stabilization, serotonin metabolism, and BDNF pathways, achieving comparable anxiolysis without sedation or dependence. Kasian et al. (2017) demonstrated that co-administration of Selank enhanced diazepam’s anxiolytic effect, suggesting complementary rather than redundant mechanisms. While diazepam and similar traditional medications present significant safety risks including tolerance and withdrawal syndrome, research suggests that Selank avoids these limitations.
Selank vs. Phenibut: Phenibut (β-phenyl-γ-aminobutyric acid) is a GABA-B receptor agonist and weak GABA-A agonist with documented anxiolytic and sedative properties. Unlike Selank, phenibut carries significant risks of tolerance, dependence, and withdrawal syndrome. Selank’s regulatory peptide mechanism, multi-target pharmacology, and absence of dependency risks represent a fundamentally different pharmacological approach to anxiety modulation without the cognitive dulling associated with phenibut use.
Browse Selank and Semax in our research catalog, or explore our full Research Articles collection for additional peptide research.
Research Dosage Protocols in Published Studies
The following describes dosages used in published research studies and is for research reference only. This is not medical advice.
Published Selank peptide research has utilized the following dosage ranges in controlled laboratory settings. Researchers should note that the most effective therapy dose varied across studies and models, and a user’s exact dose in any research protocol should be determined by the specific experimental parameters:
- Intranasal administration (clinical research): Intranasal Selank has been studied at doses of 0.15 mg per administration, delivered via nasal spray, typically administered 3 times daily in published Russian clinical trials for generalized anxiety disorder
- Intraperitoneal administration (preclinical): Doses of 100–300 μg/kg have been used in rat and mouse models, with 300 μg/kg being the most commonly reported research dose
- Injectable Selank (preclinical): Subcutaneous administration at 0.3 mg/kg/day was used in the Kolik et al. (2019) neuroprotection studies
Intranasal administration has been the preferred route in clinical research settings due to optimal peptide delivery to the central nervous system (Zolotarev et al., 2006; Ashmarin et al., 2008). The metabolic stability conferred by the glyproline modification extends Selank’s biological half-life compared to native tuftsin, supporting less frequent administration. For proper reconstitution of research peptides, see our Peptide Reconstitution Guide.
Published Research Studies and Citations
The following peer-reviewed publications form the evidence base for selank peptide research:
1. Seredenin SB, Kozlovskaia MM, Blednov IuA, et al. “The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction.” Zh Vyssh Nerv Deiat Im I P Pavlova, 48:153–160, 1998. PMID: 9583175
2. Zozulya AA, Kost NV, Sokolov OYu, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Bulletin of Experimental Biology and Medicine, 131(4):315–317, 2001. DOI: 10.1023/a:1017979514274
3. Kost NV, Sokolov OYu, Gabaeva MV, et al. “Semax and Selank inhibit the enkephalin-degrading enzymes from human serum.” Russian Journal of Bioorganic Chemistry, 27:156–159, 2001. DOI: 10.1023/a:1011373002885
4. Kozlovskii II, Danchev ND. “Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats.” Zh Vyssh Nerv Deiat Im I P Pavlova, 52:579–584, 2002. PMID: 12449836
5. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.” Neuroscience and Behavioral Physiology, 33:853–860, 2003. DOI: 10.1023/A:1025988519919
6. Semenova TP, Kozlovskaya MM, Zakharova NM, et al. “Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny.” Bulletin of Experimental Biology and Medicine, 144:689–691, 2007. DOI: 10.1007/s10517-007-0406-2
7. Narkevich VB, Kudrin VS, Klodt PM, et al. “Effects of Selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice.” Eksperimental’naya i Klinicheskaya Farmakologiya, 71:8–12, 2008.
8. Zozulia AA, Kost NV, Sokolov OYu, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia.” Zh Nevrol Psikhiatr Im S S Korsakova, 108:38–48, 2008. PMID: 18454096
9. Uchakina ON, Uchakin PN, Miasoedov NF, et al. “Immunomodulatory effects of selank in subjects with anxiety-asthenic disorders.” Zh Nevrol Psikhiatr Im S S Korsakova, 108:71–75, 2008. PMID: 18577961
10. Ershov FI, Uchakin PN, Uchakina ON, et al. “Antiviral activity of immunomodulator Selank in experimental influenza infection.” Voprosy Virusologii, 54:19–24, 2009. PMID: 19882898
11. Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. “Experimental optimization of learning and memory processes by selank.” Eksp Klin Farmakol, 73:2–5, 2010. PMID: 20919548
12. Kolomin T, Shadrina M, Slominsky P, et al. “A new generation of drugs: synthetic peptides based on natural regulatory peptides.” Neuroscience and Medicine, 4:223–252, 2013.
13. Medvedev VE, et al. “Comparison of Selank and phenazepam efficacy in phobic-anxiety and somatoform disorders.” Zh Nevrol Psikhiatr Im S S Korsakova, 2014.
14. Volkova A, Shadrina M, Kolomin T, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology, 7:31, 2016. DOI: 10.3389/fphar.2016.00031
15. Kasian A, Kolomin T, Andreeva L, et al. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Disease Markers, 2017:5091027, 2017. DOI: 10.1155/2017/5091027
16. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. “Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.” Protein and Peptide Letters, 25(10):914–923, 2018. DOI: 10.2174/0929866525666180925144642
17. Kolik LG, et al. “Selank peptide prevents ethanol-induced cognitive impairment in aged rats.” Bulletin of Experimental Biology and Medicine, 2019.
18. Panikratova YR, Lebedeva IS, Sokolov OY, et al. “Functional Connectomic Approach to Studying Selank and Semax Effects.” Bulletin of Experimental Biology and Medicine, 168:560–564, 2020. DOI: 10.1007/s10517-020-04750-4
Frequently Asked Questions About Selank Peptide Research
What is Selank peptide and how was it developed?
Selank (TP-7) is a synthetic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with the sequence Thr Lys Pro Arg-Pro-Gly-Pro. It was created by extending the naturally occurring immune peptide tuftsin (a fragment of immunoglobulin G heavy chain) with a Pro-Gly-Pro glyproline sequence to enhance metabolic stability. Selank is approved in Russia for generalized anxiety disorder research but is not FDA-approved. All Selank peptide products from Iron Peak Peptides are intended for research purposes only and are not for human consumption.
How does Selank produce anxiolytic effects without sedation?
Research suggests that Selank acts as a positive allosteric modulator of GABA receptors through a binding site distinct from the classical benzodiazepine site (Vyunova et al., 2018). Additionally, Selank administration upregulates orexin (hypocretin) gene expression—a wake-promoting neuropeptide—by over 100-fold at 3 hours post-administration (Volkova et al., 2016). This combination of GABAergic anxiolysis with orexinergic wakefulness promotion may explain the absence of sedation and cognitive dulling observed in both animal and clinical studies.
What is the relationship between Selank and enkephalin stabilization?
Selank dose-dependently inhibits enkephalin-degrading enzymes (enkephalinases) with an IC₅₀ of 15 μM, surpassing the potency of established peptidase inhibitors bacitracin and puromycin (Zozulya et al., 2001). By stabilizing endogenous enkephalins—the body’s own opioid peptides—Selank amplifies natural anxiolytic and analgesic signaling without directly activating opioid receptors, thereby avoiding tolerance and dependence.
Does Selank present significant safety risks compared to benzodiazepines?
Published research and clinical studies indicate that Selank does not present significant safety risks comparable to those of benzodiazepine tranquilizers. Traditional benzodiazepines carry dependency risks, withdrawal syndrome potential, and cognitive impairment. In contrast, research suggests that Selank does not produce sedation, tolerance, dependence, or cognitive dulling. However, Selank remains a research compound classified among certain bulk drug substances and comprehensive long-term safety data in Western research contexts is still being developed.
How does Selank compare to Semax for research purposes?
Both peptides share a Pro-Gly-Pro glyproline stabilizing sequence and were developed at the same Russian institute. However, Selank derives from tuftsin (a naturally occurring immune peptide) and primarily exhibits anxiolytic and immunomodulatory properties, while Semax derives from ACTH₄₋₁₀ (a melanocortin fragment) and primarily exhibits nootropic and neuroprotective properties. fMRI research by Panikratova et al. (2020) confirmed distinct brain connectivity signatures for each peptide.
What immune modulation effects has Selank research demonstrated, and what administration routes have been used?
Published research has documented that Selank regulates cytokine balance within the immune system (including IL-6 modulation), activates monocytes, and demonstrates antiviral activity against influenza virus through Th1/Th2/Treg cytokine equilibrium modulation (Ershov et al., 2009; Uchakina et al., 2008). These immune modulation properties are consistent with Selank’s origin as a tuftsin analog. Regarding administration, intranasal administration via nasal spray has been the primary route for intranasal Selank delivery in clinical literature, shown to be optimal for delivery to the central nervous system (Zolotarev et al., 2006). In preclinical studies, researchers have used both intranasal and intraperitoneal routes at doses typically ranging from 100–300 μg/kg. Injectable Selank has also been employed in certain research protocols. These are published research protocols and do not constitute dosage recommendations.
Why Purchase Selank from Iron Peak Peptides?
Iron Peak Peptides is committed to providing researchers with the highest-quality Selank peptide for laboratory investigations. Our Selank 5mg product undergoes rigorous third-party testing to ensure ≥98% purity, proper peptide identity, and freedom from contaminants. Every batch includes a quality assurance documentation with HPLC and mass spectrometry verification.
Researchers studying the central nervous system effects of regulatory peptides can also explore our catalog of related compounds including Semax 15mg, Pinealon 20mg, BPC-157 10mg, Epithalon 20mg, and NAD+ 500mg. For comprehensive guidance on peptide handling, visit our Peptide Reconstitution Guide and Peptide Storage Guide.
Research Disclaimer
The information in this article is provided for educational and research purposes only. Selank is a research peptide classified among certain bulk drug substances and is not approved by the FDA for any medical use. This content is not intended to diagnose, treat, cure, or prevent any disease. Selank is not for human consumption. All research referenced herein was conducted under controlled laboratory or clinical research conditions by qualified investigators. Iron Peak Peptides products are sold exclusively for in vitro research, laboratory experimentation, and educational purposes. Always consult applicable regulations and institutional review requirements before conducting peptide research.
{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “What is Selank peptide and how was it developed?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Selank (TP-7) is a synthetic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was created by extending the naturally occurring immune peptide tuftsin with a Pro-Gly-Pro glyproline sequence to enhance metabolic stability. Selank is approved in Russia for generalized anxiety disorder research but is not FDA-approved. All Selank peptide products from Iron Peak Peptides are intended for research purposes only.”
}
},
{
“@type”: “Question”,
“name”: “How does Selank produce anxiolytic effects without sedation?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Research suggests that Selank acts as a positive allosteric modulator of GABA receptors through a binding site distinct from the classical benzodiazepine site. Additionally, Selank administration upregulates orexin gene expression by over 100-fold, promoting wakefulness. This combination of GABAergic anxiolysis with orexinergic wakefulness promotion may explain the absence of sedation observed in studies.”
}
},
{
“@type”: “Question”,
“name”: “What is the relationship between Selank and enkephalin stabilization?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Selank dose-dependently inhibits enkephalin-degrading enzymes with an IC50 of 15 μM, surpassing established peptidase inhibitors. By stabilizing endogenous enkephalins, Selank amplifies natural anxiolytic and analgesic signaling without directly activating opioid receptors, thereby avoiding tolerance and dependence.”
}
},
{
“@type”: “Question”,
“name”: “Does Selank present significant safety risks compared to benzodiazepines?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Published research and clinical studies indicate that Selank does not present significant safety risks comparable to benzodiazepines. Traditional benzodiazepines carry dependency risks, withdrawal syndrome potential, and cognitive impairment. Research suggests Selank does not produce sedation, tolerance, dependence, or cognitive dulling. However, Selank remains a research compound and comprehensive long-term safety data is still being developed.”
}
},
{
“@type”: “Question”,
“name”: “How does Selank compare to Semax for research purposes?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Both peptides share a Pro-Gly-Pro glyproline stabilizing sequence and were developed at the same Russian institute. Selank derives from tuftsin and primarily exhibits anxiolytic and immunomodulatory properties, while Semax derives from ACTH and primarily exhibits nootropic and neuroprotective properties. fMRI research confirmed distinct brain connectivity signatures for each peptide.”
}
},
{
“@type”: “Question”,
“name”: “What immune modulation effects has Selank research demonstrated, and what administration routes have been used?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Published research has documented that Selank regulates cytokine balance including IL-6 modulation, activates monocytes, and demonstrates antiviral activity against influenza virus through Th1/Th2/Treg cytokine equilibrium modulation. Regarding administration, intranasal delivery via nasal spray has been the primary route in clinical literature, shown optimal for CNS delivery. In preclinical studies, both intranasal and intraperitoneal routes at 100-300 μg/kg have been used. These are published research protocols and do not constitute dosage recommendations.”
}
}
]
}
🔬 Explore Research Peptides
- BPC-157/TB-500 Blend 10mg/10mg (20mg) — $110.00
- Cagrilintide 10mg — $89.00
- BAM15 50mg – 60 Tablets — $179.00
- SNAP-8 10mg — $49.00
